A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

ClinicalTrials.gov ID: NCT06979336

Public ClinicalTrials.gov record NCT06979336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.

Study identification

NCT ID: NCT06979336
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 224 participants

Conditions and interventions

Conditions

Ulcerative Colitis

Interventions

RO7837195 Drug
RO7837195 Matched Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2025 (Actual)
Primary completion: Aug 25, 2027 (Estimated)
Completion: Oct 31, 2028 (Estimated)
Last update posted: Sep 28, 2026

2025 – 2028

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Gastro Care Institute	Lancaster	California	93534	Recruiting
Medical Associates Research Group, Inc.	San Diego	California	92123	Recruiting
Peak Gastroenterology Associates	Colorado Springs	Colorado	80907	Recruiting
Clinical Research of Osceola, LLC	Kissimmee	Florida	34741	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
Intercity Gastroenterology	Fresh Meadows	New York	11366	Recruiting
Monroe Biomedical Research	Monroe	North Carolina	28112	Recruiting
University of Utah Hospitals & Clinics	Salt Lake City	Utah	84132	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06979336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2026 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06979336 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →